Corcept Therapeutics to host two- part webinar » 04:5507/3007/30/21
Management holds a…
Management holds a two-part webinar on July 23 at 10 am and July 30. Webcast Link
Corcept Therapeutics sees FY21 revenue $355M-$385M, consensus $370.69M 16:2807/2907/29/21
Corcept Therapeutics reports Q2 EPS 30c, consensus 16c » 16:2707/2907/29/21
Reports Q2 revenue…
Reports Q2 revenue $91.59M, consensus $86.84M. "Diminishing COVID-19 public health restrictions and the availability of safe and effective vaccines have allowed our commercial business to resume growing," said Joseph Belanoff, Corcept's CEO. "Our second quarter results reflect the fact that physicians are seeing their patients more frequently, which allows them to diagnose and optimally treat those who have Cushing's syndrome. Provided COVID-19 restrictions continue to abate - as we believe they will - we expect growth to continue. Korlym is an excellent treatment for hypercortisolism and there are many eligible patients who have yet to receive it. Our planned successor to Korlym, relacorilant, which is currently in its pivotal trial, promises to be an even better medication."
Anavex announces new data on ANAVEX 2-73 » 07:2407/2907/29/21
Anavex Life Sciences…
Anavex Life Sciences reported new data that established ANAVEX 2-73 to be a preventive treatment in the pharmacological model of Alzheimer's disease. Pre-treatment with ANAVEX 2-73, repeated once daily for one week before the Abeta challenge was protective in the Abeta25-35 peptide model of Alzheimer's disease in mice. ANAVEX 2-73 significantly and dose-dependently prevented Abeta25-35-induced biomarker-correlated cognitive impairments, which were assessed one week after the Abeta insult during which no further ANAVEX 2-73 treatment took place. ANAVEX 2-73 activates the sigma-1 receptor. "We are excited about this data, which indicates the potential expansion for the ANAVEX 2-73 platform to find an effective Alzheimer's prevention therapy, which might benefit the entire field," said Christopher U. Missling, PhD, President & Chief Executive Officer of Anavex. "In addition to finding treatment options for Alzheimer's disease, we are also striving to find effective prevention therapies for this devastating disease, and this data might help advance this endeavor to address an area of high unmet medical need." This data seems to be consistent with the effect of ANAVEX 2-73 on cognition assessed in the recently completed placebo-controlled Phase 2 study of 132 patients with Parkinson's disease dementia with once-daily administration of oral 30 mg ANAVEX(R)2-73, 50 mg ANAVEX 2-73 and placebo for 14 weeks.
GameStop to rebrand EB Games in Canada » 09:4607/2807/28/21
GameStop announced that…
GameStop announced that the company plans to rebrand EB Games in Canada. By the end of this year, EB Games' Canadian locations and online store will assume the GameStop brand and name. This decision follows the receipt of feedback from valued customers and stockholders.
|Over a week ago|
Lakeland Financial to replace GameStop in S&P 600 at open on 8/4 17:2707/2707/27/21
GameStop to replace Weingarten Realty in S&P 400 at open 8/4 » 17:2507/2707/27/21
GME, WRI, KIM
Kimco Realty (KIM) is…
Kimco Realty (KIM) is acquiring Weingarten Realty Investors (WRI) in a deal expected to be completed on or about that date pending final conditions.
Game On: Activision Blizzard sued in California over workplace discrimination » 12:4907/2707/27/21
MSFT, SQNXF, NTDOY, SONY, EA, TTWO, ATVI, TCEHY, KKR, DIS, NFLX, GME, T, INTC
"Game On" is The Fly's…
Cognyte initiated with an Outperform at William Blair » 07:0807/2707/27/21
William Blair analyst…
William Blair analyst Louie DiPalma last night initiated coverage of Cognyte (CGNT) with an Outperform rating and no price target. With the proliferation of ransomware cyber incidents and the "explosion" in digital data, Cognyte should benefit from elevated demand for software tools to analyze unstructured data from a wide variety of endpoints, DiPalma tells investors in a research note. Cognyte's software is used by more than 400 government customers and over 600 enterprises, the analyst points out. He says Cognyte's software "successfully competes" for a $30B total addressable market against vendors such as FireEye (FEYE), Palantir (PLTR), CrowdStrike (CRWD), Magnet Forensics (MAGT.TO) and Motorola Solutions (MSI).DiPalma expects that Cognyte will trade at a multiple range between 18 times and 20 times EBITDA, which implies a stock price of between $27 and $30.
Cognyte initiated with an Outperform at William Blair » 19:0907/2607/26/21
William Blair analyst…
William Blair analyst Louie DiPalma initiated coverage of Cognyte with an Outperform rating.